Answers are grounded in this paper and cite their sources.
Immunotherapy has dramatically improved the prognosis for patients with melanoma and has become the cornerstone of treatment for those with advanced disease. The role of immunotherapy continues to expand with multiple new agents approved in the adjuvant as well as metastatic setting, as first-line therapy and beyond. We review the currently approved drugs for the treatment of melanoma, along with clinical trial data, adverse side effects, response assessment and future directions.
No takes yet. Share an insight, caveat, or question.
Feld et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: